ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock traders acquired 23,649 call options on the company. This represents an increase of 308% compared to the average daily volume of 5,801 call options.

Institutional Trading of ImmunityBio

Several institutional investors and hedge funds have recently modified their holdings of IBRX. Barclays PLC lifted its position in shares of ImmunityBio by 46.5% during the 2nd quarter. Barclays PLC now owns 60,469 shares of the company's stock worth $168,000 after buying an additional 19,181 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of ImmunityBio during the 3rd quarter valued at about $57,000. Traynor Capital Management Inc. bought a new stake in shares of ImmunityBio during the 3rd quarter valued at about $25,000. Exchange Traded Concepts LLC boosted its holdings in ImmunityBio by 22.3% in the third quarter. Exchange Traded Concepts LLC now owns 58,136 shares of the company's stock worth $98,000 after acquiring an additional 10,596 shares in the last quarter. Finally, Aire Advisors LLC bought a new position in ImmunityBio in the third quarter worth approximately $25,000. 8.58% of the stock is currently owned by institutional investors.

ImmunityBio Stock Up 11.1 %

Shares of NASDAQ:IBRX traded up $0.55 during trading on Tuesday, reaching $5.49. 30,619,100 shares of the company traded hands, compared to its average volume of 4,385,710. The company's 50 day moving average is $5.17 and its two-hundred day moving average is $4.11. The firm has a market capitalization of $3.72 billion, a PE ratio of -4.68 and a beta of 1.23. ImmunityBio has a 52 week low of $1.25 and a 52 week high of $6.93.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings data on Tuesday, March 19th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). The company had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.03 million. As a group, research analysts anticipate that ImmunityBio will post -0.68 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Piper Sandler upped their target price on ImmunityBio from $4.00 to $5.00 and gave the company a "neutral" rating in a research report on Monday, March 25th.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.